Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Jan 11 2022|
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy